Literature DB >> 3193479

Cryospectrophotometric determination of tumor intravascular oxyhemoglobin saturations: dependence on vascular geometry and tumor growth.

B M Fenton1, E K Rofstad, F L Degner, R M Sutherland.   

Abstract

To delineate the complex relationships between overall tumor oxygenation and vascular configuration, intravascular oxyhemoglobin (HbO2) saturation distributions were measured with cryospectrophotometric techniques. Four factors related to vascular morphometry and tumor growth were evaluated: a) vessel diameter, b) distance of vessel from the tumor surface, c) tumor volume, and d) vascular density. To measure intertumor heterogeneity, two murine sarcomas (RIF-1 and KHT) and two human ovarian carcinoma xenografts (OWI and MLS) were utilized. In contrast to skeletal muscle, a preponderance of very low HbO2 saturations was observed for both large and small tumors of all lines. Saturations up to about 90% were also generally present, however, even in very large tumors. Variations in vascular configuration were predominantly tumor-line dependent rather than due to inherent characteristics of the host vasculature, and widely disparate HbO2 distributions were found for alternate lines implanted in identical host mice. Although peripheral saturations remained fairly constant with tumor growth, HbO2 values were markedly lower for vessels nearer the tumor center and further decreased with increasing tumor volume. HbO2 saturations did not change substantially with increasing vascular density (except for KHT tumors), although density did decrease with increasing distance from tumor surface. Combined effects of vessel diameter, tumor volume, and vessel location on HbO2 saturations were complex and varied markedly with both tumor line and vessel class. For specific classes, HbO2 distributions correlated closely with radiobiological hypoxic fractions, i.e., for tumor lines in which hypoxic fraction increased substantially with tumor volume, corresponding HbO2 values decreased, while for lines in which hypoxic fraction remained constant, HbO2 values also were unchanged. Although these trends may also be a function of differing oxygen consumption rates between tumor lines, functional alterations in the rapidly expanding tumor vasculature undoubtedly play a primary role in explaining spatial oxygenation heterogeneities.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3193479     DOI: 10.1093/jnci/80.20.1612

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  6 in total

Review 1.  Near-infrared optical mammography for breast cancer detection with intrinsic contrast.

Authors:  Sergio Fantini; Angelo Sassaroli
Journal:  Ann Biomed Eng       Date:  2011-10-05       Impact factor: 3.934

2.  Temporal heterogeneity in blood supply in human tumor xenografts.

Authors:  Kjetil G Brurberg; Jon-Vidar Gaustad; Camilla S Mollatt; Einar K Rofstad
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

3.  Blood supply in melanoma xenografts is governed by the morphology of the supplying arteries.

Authors:  Jon-Vidar Gaustad; Trude G Simonsen; Kjetil G Brurberg; Else Marie Huuse; Einar K Rofstad
Journal:  Neoplasia       Date:  2009-03       Impact factor: 5.715

4.  Targeting the tumour vasculature: exploitation of low oxygenation and sensitivity to NOS inhibition by treatment with a hypoxic cytotoxin.

Authors:  Jennifer H E Baker; Alastair H Kyle; Kirsten L Bartels; Stephen P Methot; Erin J Flanagan; Andrew Balbirnie; Jordan D Cran; Andrew I Minchinton
Journal:  PLoS One       Date:  2013-10-28       Impact factor: 3.240

Review 5.  Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.

Authors:  Jinsong Hu; Els Van Valckenborgh; Eline Menu; Elke De Bruyne; Karin Vanderkerken
Journal:  Dis Model Mech       Date:  2012-11       Impact factor: 5.758

6.  Overexpression of VEGF121, but not VEGF165 or FGF-1, improves oxygenation in MCF-7 breast tumours.

Authors:  B M Fenton; S F Paoni; W Liu; S-Y Cheng; B Hu; I Ding
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.